Cell-free Entry of Human T-Cell Leukemia Virus Type 1 to Mouse Cells

Renqing Feng, 1 Ayako Kabayama,1 Kazuhiko Uchida,1 Hiroo Hoshino2 and Masanao Miwa1, 3
1Department of Biochemistry and Molecular Oncology, Institute of Basic Medical Sciences and Center for Tsukuba Advanced Research Alliance, University of Tsukuba, 1-1-1 Tennoudai, Tsukuba, Ibaraki 305-8575 and 2Department of Virology and Preventive Medicine, Gunma University School of Medicine, 3-39-22 Showa-machi, Maebashi, Gunma 371-8511

Human T-cell leukemia virus type 1 (HTLV-1) is the etiologic agent for adult T-cell leukemia and HTLV-1-associated myelopathy/tropical spastic paraparesis. Recently we infected newborn mice by inoculating HTLV-1-producing human cells, and found that T-cells, B-cells and granulocytes were infected in vivo. To understand the mechanism of viral-cell interaction and the pathogenesis of HTLV-1 using the mouse model, it is important to clarify the cellular tropism using a cell-free HTLV-1 transmission system. We employed a highly transmissible cell-free HTLV-1 produced by a feline kidney cell line, c77, and studied the susceptibility of 9 kinds of mouse cell lines, EL4, RLm1, CTLL-2, J774.1, DA-1, Ba/F3, WEHI-3, NIH3T3 and B1, and two kinds of human cell lines, Molt-4 and Hut78. HTLV-1 proviral sequence was found by PCR in all 9 mouse cell lines as well as in 2 human cell lines and viral entry was blocked with sera from an HTLV-1 carrier and an adult T-cell leukemia patient. Unexpectedly, mouse cell lines EL4 and RLm1 and human cell lines Molt-4 and Hut78 showed similar efficiency for viral entry. These results suggest a wide distribution of HTLV-1 receptor in mouse cells.

Key words: Entry — Human T-cell leukemia virus type 1 — Cell-free transmission — Mouse cell lines — Receptor

MATERIALS AND METHODS

Cells and cell culture The HTLV-1-producing cell line used in this experiment was c77 feline kidney cell line.12 The mouse cell lines used as target cells were EL4 (CD4+ T-cell),13 RLm1 (CD4+, CD8+ T-cell),14 CTLL-2 (CD8+ T-cell),15 J774.1 (macrophage),16 Ba/F3 (Pro-B-cell),17 DA-1 (myeloid cell),18 WEHI-3 (myeloma cell),19 NIH3T3 (fibroblast cell)20 and B1(Leydig cell).21 Human

1To whom correspondence should be addressed.
E-mail: m-miwa@md.tsukuba.ac.jp
Entry of Cell-free HTLV-1 into Mouse Cells

T-cell lines, Hut78 (CD4+, CD8−)22 and Molt-4 (CD3+, CD4+),23 were also used as target cells. Hut78, Molt4, EL4, RLm1, CTLL-2, J774.1, WEHI-3, Ba/F3 and DA-1 were maintained in RPMI1640 supplemented with 10% fetal calf serum. To this 50 U/ml recombinant human interleukin-2 (Shionogi, Saitama) was added for CTLL-2, and 10% of WEHI-3 cell-conditioned medium as a source of interleukin-3 for Ba/F3 and DA-1. c77 was maintained in Eagle’s minimum essential medium (EMEM) supplemented with 10% fetal calf serum. NIH3T3 was maintained in Dulbecco’s modified Eagle’s medium (DMEM) with 10% fetal calf serum. B1 was maintained in EMEM supplemented with 10% fetal calf serum and 10−8 M β-estradiol and 0.1 µg/ml insulin. EL4 and RLm1 were the gifts of Drs. T. Hanjo (Kyoto University) and H. Nakaochi (University of Tsukuba), respectively. B1 was obtained from the Japanese Collection of Research Biorepositories Cell Bank (Osaka). CTLL-2, J774.1, WEHI-3, Ba/F3 and DA-1 were obtained from RIKEN Cell Bank (Tsukuba).

Virus preparation Cell-free HTLV-1 had been prepared as described 11) with a slight modification. c77 cells were seeded at 5×105 per ml in culture medium, and incubated for 2 days. The medium was replaced by fresh medium which was harvested after incubation for 24 h. Cells and debris were removed from the culture supernatant by centrifugation for 15 min at 800g, then filtered through a 0.45-µm-pore-size filter. In some experiments, the filtrate was further incubated with 80 U/ml of RNase-free DNase I (Promega, Madison, WI) for 1 h at 37°C. The filtrates were used immediately. The HTLV-1 p19 antigen in the virus preparation was measured.

Inoculation of target cells with cell-free HTLV-1 and detection of provirus and p19 antigen Mouse cell lines, at a concentration of 5–10×103 cells per ml, were inoculated with the virus preparation for 24 h at 37°C. The cells were harvested, washed twice with phosphate-buffered saline (PBS) and divided into two aliquots. One of the aliquots was lysed by lysis buffer (10 mM Tris-HCl, pH 8.3, 1 mM EDTA, 0.45% NP-40, 0.45% Tween 20 and 30 µg/ml protease K) and incubated for 5 h at 55°C. The HTLV-1 pX sequence in the lysates was determined by PCR and subsequent Southern hybridization. The other aliquot of cells was maintained in the culture medium for a further 24 h. The cells were then harvested as above for analysis of HTLV-1 provirus by PCR. The culture supernatants were collected to measure the p19 antigen of HTLV-1 by using an HTLV-1 p19 ELISA kit (Cellular Products Inc., New York, NY) according to the manufacturer’s instructions. The lysate of 5×104 cells was used for each PCR. HTLV-1 pX sequence was detected by PCR amplification (95°C for 10 min, then 50 cycles of 95°C for 1 min, 57°C for 1 min and 72°C for 1.5 min, ended by 72°C for 10 min) with Taq polymerase and Southern hybridization, as described previously.10) The mouse c-myc sequence or human β-globin sequence which served as the internal control to assure the quality of the template was amplified in the same reaction tube as multiplex PCR.10)

The primers for the pX region were 5′-CGGATAACCCGAGTCTACGTGT-3′ (nt 7336–7355) and 5′-GAGCGGATAACGCCTCCATC-3′ (nt 7475–7494), those for mouse c-myc were 5′-ACACGCTTGTAAAGCCTGAC-3′ (nt 4069–4088) and 5′-GGTTAAGCTTTTGAAGCATGCA-3′ (nt 4394–4413) and those for human β-globin were 5′-GTTGGCCAATCTACTCCCAAGG-3′ (nt 85–106) and 5′-TGTTCTCTTTAACCTGTCTTG-3′ (nt 325–346). The probe for the pX region was 5′-CTGTGTGACACGACCTGGTG-3′ (nt 7363–7383). To exclude the possibility of contamination of the pX-containing DNA fragments from c77 cells, the filtrate of the culture supernatant of c77 cells was subjected to PCR. Namely, a mixture of 12.5 µl of the cell-free virus preparation and 1 µg of DNA of HTLV-1-negative Hut78 cell was used as a template for PCR to detect pX sequence.

Neutralization of HTLV-1 entry To analyze the neutralizing activity of cell-free HTLV-1 entry, the virus preparation was incubated with various dilutions of serum at 37°C for 60 min, and then used to inoculate the target cells. Sera from a healthy donor, an HTLV-1 carrier and an ATL patient were used. The titers of anti-HTLV-1 antibodies in the sera were assayed with a particle agglutination kit (Serodia HTLV-1; Fujirebio, Tokyo). The titer of anti-HTLV-1 antibodies in the serum from a healthy donor, an HTLV-1 carrier and an ATL patient were used. The titers of anti-HTLV-1 antibodies in the serum from a non-infected healthy donor was less than 1:16, that from an HTLV-1 carrier 1:4096, and that from an ATL patient was 1:4413. The probe for the pX region was 5′-CTGTGTGACACGACCTGGTG-3′ (nt 7363–7383). To exclude the possibility of contamination of the pX-containing DNA fragments from c77 cells, the filtrate of the culture supernatant of c77 cells was subjected to PCR. Namely, a mixture of 12.5 µl of the cell-free virus preparation and 1 µg of DNA of HTLV-1-negative Hut78 cell was used as a template for PCR to detect pX sequence.

Susceptibility of human and mouse cells to cell-free HTLV-1 In order to check the susceptibility of human and mouse cells to cell-free HTLV-1, the virus preparation was serially diluted with culture medium and then added to the target cells. Sera from a healthy donor, an HTLV-1 carrier and an ATL patient were used. The titers of anti-HTLV-1 antibodies in the sera were assayed with a particle agglutination kit (Serodia HTLV-1; Fujirebio, Tokyo). The titer of anti-HTLV-1 antibodies in the serum from a non-infected healthy donor was less than 1:16, that from an HTLV-1 carrier 1:4096, and that from an ATL patient was 1:2048. Sera were heated at 56°C for 30 min and filtered through a 0.45-µm-pore-size filter (Code, 03CP045AS, ADVANTEC, Tokyo) for sterilization before use. Antibody neutralization was performed by preincubating the virus preparation with serum for 1 h at 37°C before use for inoculation to the target cells.

RESULTS

Validity of cell-free preparation as a source of HTLV-1 virion Virus preparation from HTLV-1-producing c77 cells was filtered through a 0.45-µm-pore-size filter, treated with 80 U/ml of RNase-free DNase I for 1 h at 37°C, and used to inoculate Hut78 cells, an HTLV-1 sus-
Fig. 1. A. Entry of cell-free HTLV-1 into Hut78 cells. Hut78 cells were harvested at 0 and 24 h after inoculation with cell-free HTLV-1 treated with RNase-free DNase I for 1 h at 37°C. The harvested cells were heated at 95°C for 10 min to inactive DNase I. Quadruplicate assays for HTLV-1 pX and human β-globin sequences from cells harvested at 0 h (lanes 1, 2, 3 and 4) and 24 h (lanes 5, 6, 7 and 8) were analyzed by PCR. The set of ethidium bromide staining patterns (upper panel) and Southern hybridization patterns (lower panel) are presented. Human β-globin band, which serves as an internal control, was seen by ethidium bromide staining. Uninfected Hut78 cell DNA was used as a negative control (N). HTLV-1-immortalized human ATL-1K cell DNA mixed with 1 μg of Hut78 cell DNA was used as a positive control (P). M indicates DNA size markers. B. The filtrate of cell-free HTLV-1 inoculum is free of proviral DNA. The virus preparation was mixed with 1 μg of carrier DNA, Hut78 cell DNA, as described in “Materials and Methods.” HTLV-1 pX and human β-globin sequences were analyzed by PCR. Sets of ethidium bromide staining patterns (upper panel) and Southern hybridization patterns (lower panel) are presented. HTLV-1-immortalized human ATL-1K cell DNA mixed with 1 μg of uninfected Hut78 cell DNA served as positive controls (P1 and P2). Uninfected Hut78 cell DNA served as negative controls (N1 and N2). M indicates DNA size marker. Lanes 1, 2, 3 and 4 were treated with RNase-free DNase I, and lanes 5, 6, 7 and 8 were not treated with RNase-free DNase I.

ceptible human T-cell line. After 0 and 24 h of cultivation, Hut78 cells were harvested, heated for 10 min at 95°C to inactive any remaining DNase I and stored at −20°C until PCR. As shown in Fig. 1A, HTLV-1 pX sequence was detected from the DNA of Hut78 cells incubated for 24 h after inoculation, but not at 0 h.

The filtered virus preparation was assayed by PCR for any possible contaminating DNA fragments of c77 cells which contain the pX sequence. As shown in Fig. 1B, no amplified HTLV-1 pX sequence was found in the virus preparation treated or untreated with 80 U/ml RNase-free DNase I for 1 h at 37°C, indicating that there is no detectable amount of DNA fragments with pX sequence, but there are infectious particles of HTLV-1, in the viral preparation. These data strongly suggest that the cell-free filtrate of c77 cells contains infectious particles of HTLV-1, but not significant DNA fragments from c77 cells containing HTLV-1 provirus.

Entry of cell-free HTLV-1 into mouse cell lines Nine mouse cell lines were inoculated with cell-free HTLV-1 for 24 and 48 h at 37°C. HTLV-1 pX sequence was detectable by PCR at 24 h (data not shown) and 48 h after inoculation from the lysates of all 9 mouse cell lines as shown in Fig. 2.

Blocking of HTLV-1 entry by anti-HTLV-1 sera Virus preparations were incubated with RNase-free DNase I and with serially diluted normal human serum or serum from an HTLV-1 carrier. Then they were used to inoculate either EL-4 or WEHI-3 cells. After 48 h of incubation, the cell lysates of EL-4 or WEHI-3 were analyzed by PCR for pX sequence. As shown in Fig. 3, pX sequence was detected from both EL-4 and WEHI-3 cells treated with normal human serum-treated virus preparation, but not by HTLV-1 carrier serum-treated virus preparation, even at 100-fold serum dilution. These results suggest that entry of HTLV-1 is mediated by a specific interaction between HTLV-1 and the cell membrane, presumably an HTLV-1 receptor.

Quantification of viral DNA molecules in target cells As shown in Table I, while pX sequence of HTLV-1 was positive until 10-fold dilution of the lysates, it was negative at 100-fold dilution in the case of medium alone or normal human serum. This indicates that the number of viral DNA molecules in the cells as determined by semiquantitative PCR is more than 10 but less than 100 per 5×10⁴ target cells. There was no significant difference among the 4 mouse cell lines. Again, the entry of HTLV-1 was blocked by anti-HTLV-1 antibody, as was clear at 10-fold dilution of the lysates in the presence of the serum from an ATL patient.
Similar susceptibility of human and mouse cell lines to entry of cell-free HTLV-1

Cell-free HTLV-1 preparation, the culture supernatant of c77 cells, was serially diluted and used to inoculate human T cell lines Molt-4 and Hut78, and mouse T cell lines EL4 and RLm1. As shown in Fig. 4, HTLV-1 pX sequence was positive at viral dilutions of 1/1 and 1/5 in Molt-4 and EL4 cell lysates, and at the viral dilution of 1/1 in Hut78 and RLm1 cell lysates. These results indicate that human T cell lines and mouse T cell lines are similarly susceptible to cell-free HTLV-1.

Analyses for viral protein expression

The HTLV-1 p19 antigen concentration in the culture supernatants of c77 cells and the target cells 48 h after inoculation was assayed by using an HTLV-1 p19 ELISA kit. There was 28.3 ng/ml p19 antigen in the cell-free filtrate of c77 cells. The concentration of p19 antigen in the supernatants of all 9 mouse cell lines at 48 h after infection with cell-free HTLV-1 was below the level of detectability of 25 pg/ml.

DISCUSSION

We demonstrated that cell-free HTLV-1 particles produced by a feline kidney cell line can enter mouse cells as efficiently as human cells. This transmission is inhibited by anti-HTLV-1 antibody. These data suggest that mouse cells have HTLV-1 receptor.

To establish an efficient strategy to approach the problem of viral-cell interaction and the pathogenesis of
HTLV-1 using a mouse model, it is important to study HTLV-1 tropism using an HTLV-1 transmission system. It was reported that mouse fibroblast cell lines, including LMTK− and NIH3T3 TK− cells, were very resistant to HTLV-1 infection compared to human cell lines by monitoring plaque-forming units after VSV (HTLV-1) pseudotype infection and by syncytia formation assay after cocultivation with the HTLV-1 producing human cell line C91/PL.7) Furthermore, the somatic-cell hybrid cell line L1q, which contains human chromosome 17q, could be infected with HTLV-1, but the parental mouse fibroblast cell line, LMTK−, could not.29) Thus, the receptor gene for HTLV-1 has been assigned to human chromosome 17q.7, 26, 27) However, Sutton and Littman reported that HIV (HTLV-1) pseudotype virus could infect mouse fibroblast LMTK− cells at 4.5% efficiency and four other LMTK− cell lines which contained at least human chromosome 17q at 0.015–2.0% efficiency as compared to a human osteosarcoma cell line, HOS cells.29)

The reason for these discrepancies is unclear. The possibilities include differences in the virus preparations, the target mouse cell lines and/or the sensitivity and specificity of the assay systems. The cell-free HTLV-1 used in earlier studies was mostly from MT-2 cells,25, 29, 30) C91/PL cells60) or HOS/PL cells.31) The filtered virus in the culture fluids of C91/PL cells could infect human lymphocytes from cord blood and peripheral blood, and that of MT-2 cells could infect human lymphocytes from cord blood only, while that of C10/MJ could infect neither of them.30) Since the native infectious particles of HTLV-1 were difficult to obtain, various kinds of pseudotype viruses have also been used for cell-free infection.7, 28, 32) We took advantage of the cell-free HTLV-1 produced by c77 cells, a feline kidney cell line, which was reported to infect human cells about 3000 times as efficiently as those from MT-2, C91/PL and HOS/PL cells.11, 33, 34) The endogenous feline xenotropic CCC retrovirus (CCC virus) was produced from c77 cells.35) However, the present work using mouse cell lines, EL-4 and WEHI-3 cells, showed complete neutralization of cell-free HTLV-1 transmission by HTLV-1 antibody-positive human sera, and we have reported that there was little or no HTLV-1 (CCC) pseudotype in the c77 culture supernatant.11) It was also reported that the supernatant of irradiated MT-2 cells contained about 250 pg/ml of HTLV-1 p19 antigen.36) The virus preparation from c77 cells used in this study contained about 100 times more p19 antigen than the reported MT-2 cell culture supernatant. Mouse cell lines used previously are mostly fibroblasts, LMTK− and LMTK− derived mouse/human hybrid cells.7, 25) Cell adhesion molecules were considered to be co-receptors for HTLV-1 transmission, based on syncytium formation assay.37) We used various kinds of cells of mouse origin to show that the receptor or co-receptor of HTLV-1 is widely distributed in mouse cells. Our data are consistent with reports that the receptor for HTLV-2, which shares a common receptor with HTLV-1,38) is widely distributed among species and cell types including murine cells, based on a highly sensitive fusion assay,39) and that the receptor for HTLV-1 was expressed on a broad range of cell lines derived from multiple species, including NIH3T3 mouse cell line, based on a highly sensitive pseudotype assay.40) The broad cell type specificities in mouse cell lines are also consistent with those in human cell lines, including U251-MG, human glioma-derived, HOS, human osteosarcoma-derived and HeLa cells.11)

HTLV-1 p19 core antigen expression in the HTLV-1-infected mouse cells could not be detected in the culture fluid. The following possibilities can be considered. The number of cells infected and amount of viral antigen expressed are too small to be detectable by the present ELISA kit, or infected cells might not express viral antigen. This possibility could be tested by examining the infectivity of HTLV-1 virion produced in the supernatant of the susceptible cells, when we obtain efficient methods of concentration of biologically active HTLV-1 particles. Our previous result that HTLV-1-infected mouse splenocytes did not express HTLV-1 Tax mRNA is consistent with the present findings.10) Human CD4/CCR5 transgenic mouse could be infected with HIV-1, but tat/rev mRNA could not be detected from spleen and lymph node RNA by RT-PCR.40) It is known that overexpression of human cyclin T enhances Tat transactivation in rodent cell lines.41) It is possible that HTLV-1-infected mouse cells lack cellular factors required for HTLV-1 gene expression.

In conclusion, efficient viral entry into various mouse cell lines was demonstrated with the cell-free HTLV-1 preparation produced by c77 cell line. These findings are relevant to further analysis of virus-cell interaction and may help to clarify the factors necessary for HTLV-1 infection.

ACKNOWLEDGMENTS

We thank Dr. H. Nakauchi for providing RLm1 cell line and Dr. T. Honjo for providing EL4 cell line. This work was supported in part by Grants-in-Aid from the Ministry of Education, Science, Sports and Culture and for the 2nd Term Comprehensive 10-year Strategy for Cancer Control and Cancer Research from the Ministry of Health and Welfare of Japan. (Received November 21, 2000/Revised January 31, 2001/ Accepted February 11, 2001)
REFERENCES

1) Poiesz, B. J., Ruscetti, F. W., Gazdar, A. F., Bunn, P. A., Minna, J. D. and Gallo, R. C. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc. Natl. Acad. Sci. USA, 77, 7415–7419 (1980).

2) Osame, M., Matsumoto, M., Usuku, K., Izumo, S., Iuchi, N., Aminli, H., Tara, M. and Igata, A. Chronic progressive myelopathy associated with elevated antibodies to human T-lymphotropic virus type I and adult T-cell leukaemia-like cells. Ann. Neurol., 21, 117–122 (1987).

3) Tajima, K. The 4th nation-wide study of adult T-cell leukemia/lymphoma (ATL) in Japan: estimates of risk of ATL and its geographical and clinical features. The T- and B-cell Malignancy Study Group. Int. J. Cancer, 45, 237–243 (1990).

4) Akagi, T., Takeda, I., Oka, T., Ohotsuki, Y., Yano, S. and Miyoshi, I. Experimental infection of rabbits with human T-cell leukemia virus type I. Jpn. J. Cancer Res., 76, 86–94 (1985).

5) Suga, T., Kameyama, T., Kinoshita, T., Shimotohno, K., Matsumura, M., Tanaka, H., Kushida, S., Ami, Y., Uchida, M., Uchida, K. and Miwa, M. Infection of rats with HTLV-I: a small-animal model for HTLV-I carriers. Int. J. Cancer, 49, 764–769 (1991).

6) Kinoshita, K., Yamanouchi, K., Ikeda, S., Momita, S., Amagasaki, T., Soda, H., Ichimaru, M., Moriuchi, R., Katamine, S., Miyamoto, T. and Hino, S. Oral infection of a common marmoset with human T-cell leukemia virus type I (HTLV-I) by inoculating fresh human milk of HTLV-I carrier mothers. Jpn. J. Cancer Res., 76, 1147–1153 (1985).

7) Sommerfelt, M. A., Williams, B. P., Clapham, P. R., Solomon, E., Goodfellow, P. N. and Weiss, R. A. Human T cell leukemia viruses use a receptor determined by human chromosome 17. Science, 242, 1557–1559 (1988).

8) Fang, J., Kushida, S., Feng, R., Tanaka, M., Kikukawa, H., Kawamura, T., Uchida, K. and Miwa, M. Integration of HTLV-I provirus into mouse transforming growth factor-α gene. Biochim. Biophys. Res. Commun., 233, 792–795 (1997).

9) Fang, J., Kushida, S., Feng, R., Tanaka, M., Kawamura, T., Abe, H., Maeda, N., Onorobi, M., Hori, M., Uchida, K. and Miwa, M. Transmission of human T-cell leukemia virus type 1 to mice. J. Virol., 72, 3952–3957 (1998).

10) Feng, R., Tanaka, M., Abe, H., Arashi, N., Sun, B., Uchida, K. and Miwa, M. Human T-cell leukemia virus type 1 can infect a wide variety of cells in mice. Jpn. J. Cancer Res., 90, 48–54 (1999).

11) Haraguchi, Y., Yang, D. W., Handa, A., Shimizu, N., Tanaka, Y. and Hoshino, H. Detection of neutralizing antibodies against human T-cell leukemia virus type 1 using a cell-free infection system and polymerase chain reaction. Int. J. Cancer, 59, 416–421 (1994).

12) Hoshino, H., Shimoyama, M., Miwa, M. and Sugimura, T. Detection of lymphocytes producing a human retrovirus associated with adult T-cell leukemia by synctia induction assay. Proc. Natl. Acad. Sci. USA, 80, 7337–7341 (1983).

13) Delamarre, L., Rosenberg, A. R., Pique, C., Pham, D., Callebaut, I. and Dokhelar, M. C. The HTLV-I envelope glycoproteins: structure and functions. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol., 13 (Suppl. 1), S85–S91 (1996).

14) Habu, S., Fukui, H., Shimamura, K., Kasai, M., Nagai, Y., Okumura, K. and Tamaoki, N. In vivo effects of anti-asialo GM1. I. Reduction of NK activity and enhancement of transplanted tumor growth in nude mice. J. Immunol., 127, 34–38 (1981).

15) Gillis, S. and Smith, K. A. Long term culture of tumour-specific cytotoxic T cells [letter]. Nature, 268, 154–156 (1977).

16) Sakagami, H., Ikeda, M. and Konno, K. Stimulation of tumor necrosis factor-induced human myelogenous leukemia cell differentiation by high molecular weight PSK subtraction. Biochem. Biophys. Res. Commun., 162, 597–603 (1989).

17) Wada, M., Uchida, H., Ikeda, M., Tsunekawa, B., Naito, N., Banba, S., Tanaka, E., Hashimoto, Y. and Honjo, M. The 20-kidalton (kDa) human growth hormone (hGH) differs from the 22-kDa hGH in the complex formation with cell surface hGH receptor and hGH-binding protein circulating in human plasma. Mol. Endocrinol., 12, 146–156 (1998).

18) Pierce, J. H., Di Fiore, P. P., Aaronson, S. A., Potter, M., Pumphrey, J., Scott, A. and Ihle, J. N. Neoplastic transformation of mast cells by Abelson-MuLV: abrogation of IL-3 dependence by a nonautocrine mechanism. Cell, 41, 685–693 (1985).

19) Metcalf, D. Clonal extinction of myelomonocytic leukemic cells by serum from mice injected with endotoxin. Int. J. Cancer, 25, 225–233 (1980).

20) Kakunaga, T. and Crow, J. D. Cell variants showing differential susceptibility to ultraviolet light-induced transformation of mast cells by Abelson-MuLV: abrogation of IL-3 dependence by a nonautocrine mechanism. Cell, 41, 685–693 (1985).

21) Hoshino, H., Shimoyama, M., Miwa, M. and Sugimura, T. Detection of lymphocytes producing a human retrovirus associated with adult T-cell leukemia by synctia induction assay. Proc. Natl. Acad. Sci. USA, 80, 7337–7341 (1983).

22) Delamarre, L., Rosenberg, A. R., Pique, C., Pham, D., Callebaut, I. and Dokhelar, M. C. The HTLV-I envelope glycoproteins: structure and functions. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol., 13 (Suppl. 1), S85–S91 (1996).

23) Habu, S., Fukui, H., Shimamura, K., Kasai, M., Nagai, Y., Okumura, K. and Tamaoki, N. In vivo effects of anti-asialo GM1. I. Reduction of NK activity and enhancement of transplanted tumor growth in nude mice. J. Immunol., 127, 34–38 (1981).

24) Gillis, S. and Smith, K. A. Long term culture of tumour-specific cytotoxic T cells [letter]. Nature, 268, 154–156 (1977).

25) Sakagami, H., Ikeda, M. and Konno, K. Stimulation of tumor necrosis factor-induced human myelogenous leukemia cell differentiation by high molecular weight PSK subtraction. Biochem. Biophys. Res. Commun., 162, 597–603 (1989).

26) Wada, M., Uchida, H., Ikeda, M., Tsunekawa, B., Naito, N., Banba, S., Tanaka, E., Hashimoto, Y. and Honjo, M. The 20-kidalton (kDa) human growth hormone (hGH) differs from the 22-kDa hGH in the complex formation with cell surface hGH receptor and hGH-binding protein circulating in human plasma. Mol. Endocrinol., 12, 146–156 (1998).

27) Pierce, J. H., Di Fiore, P. P., Aaronson, S. A., Potter, M., Pumphrey, J., Scott, A. and Ihle, J. N. Neoplastic transformation of mast cells by Abelson-MuLV: abrogation of IL-3 dependence by a nonautocrine mechanism. Cell, 41, 685–693 (1985).

28) Metcalf, D. Clonal extinction of myelomonocytic leukemic cells by serum from mice injected with endotoxin. Int. J. Cancer, 25, 225–233 (1980).

29) Kakunaga, T. and Crow, J. D. Cell variants showing differential susceptibility to ultraviolet light-induced transformation. Science, 209, 505–507 (1980).

30) Sato, B., Miyashita, Y., Maeda, Y., Noma, K., Kishimoto, S. and Matsumoto, K. Effects of estrogen and vanadate on the proliferation of newly established transformed mouse Leydig cell line in vitro. Endocrinology, 120, 1112–1120 (1987).

31) Noguchi, M., Iwamori, M., Hirano, T., Kobayashi, S., Hashimoto, H., Hirose, S. and Nagai, Y. Autoantibodies to T and B cell lines detected in serum samples from patients with systemic lupus erythematosus with lymphopenia and hypocomplementaemia. Ann. Rheum. Dis., 51, 713–716 (1992).

32) Kikukawa, R., Koyanagi, Y., Harada, S., Kobayashi, N., Hatanaka, M. and Yamamoto, N. Differential susceptibility to the acquired immunodeficiency syndrome retrovirus in cloned cells of human leukemic T-cell line Molt-4. J. Virol., 57, 1159–1162 (1986).
24) Matsumura, M., Kushida, S., Ami, Y., Uchida, K., Kameyama, T., Terano, A., Shiraki, H., Sato, H. and Miwa, M. A simple and reliable method for the detection and quantitation of the human T-cell leukemia virus type-I provirus in peripheral blood mononuclear cells of seropositive blood donors. *Jpn. J. Clin. Oncol.*, 22, 335–341 (1992).

25) Fan, N., Gavalchin, J., Paul, B., Wells, K. H., Lane, M. J. and Poiesz, B. J. Infection of peripheral blood mononuclear cells and cell lines by cell-free human T-cell lymphoma/leukemia virus type I. *J. Clin. Microbiol.*, 30, 905–910 (1992).

26) Gavalchin, J., Fan, N., Waterbury, P. G., Corbett, E., Faldasz, B. D., Peshick, S. M., Poiesz, B. J., Papsidero, L. and Lane, M. J. Regional localization of the putative cell surface receptor for HTLV-I to human chromosome 17q23.2-17q25.3. *Virology*, 212, 196–203 (1995).

27) Tajima, Y., Tashiro, K. and Camerini, D. Cloning of human chromosome 17-specific cDNAs using representational difference analysis and human-mouse hybrid cells. *Genomics*, 42, 353–355 (1997).

28) Sutton, R. E. and Littman, D. R. Broad host range of human T-cell leukemia virus type 1 demonstrated with an improved pseudotyping system. *J. Virol.*, 70, 7322–7326 (1996).

29) Yamade, I., Isono, T., Ishiguro, T. and Yoshida, Y. Comparative study of human and rabbit cell infection with cell-free HTLV-I. *J. Med. Virol.*, 39, 75–79 (1993).

30) De Rossi, A., Aldovini, A., Franchini, G., Mann, D., Gallo, R. C. and Wong Staal, F. Clonal selection of T lymphocytes infected by cell-free human T-cell leukemia/lymphoma virus type I: parameters of virus integration and expression. *Virology*, 143, 640–645 (1985).

31) Clapham, P., Nagy, K., Cheingsong-Popov, R., Exley, M. and Weiss, R. A. Productive infection and cell-free transmission of human T-cell leukemia virus in a nonlymphoid cell line. *Science*, 222, 1125–1127 (1983).

32) Trejo, S. R. and Ratner, L. The HTLV receptor is a widely expressed protein. *Virology*, 268, 41–48 (2000).

33) Fu, D. X., Haraguchi, Y., Jinno, A., Yang, D. and Hoshino, H. Identification of membrane antigens important for adsorption of human T-cell leukemia virus type I. *Res. Virol.*, 149, 383–392 (1998).

34) Jinno, A., Haraguchi, Y., Shiraki, H. and Hoshino, H. Inhibition of cell-free human T-cell leukemia virus type I infection at a postbinding step by the synthetic peptide derived from an ectodomain of the gp21 transmembrane glycoprotein. *J. Virol.*, 73, 9683–9689 (1999).

35) Fischinger, P. J., Peebles, P. T., Nomura, S. and Haapala, D. K. Isolation of RD-114-like oncornavirus from a cat cell line. *J. Virol.*, 11, 978–985 (1973).

36) Sato, Y., Ito, K., Moritoyo, T., Fujino, Y., Masuda, K., Yamaguchi, K., Mochizuki, M., Izumo, S., Osame, M. and Watanabe, T. Human T-cell lymphotropic virus type I can infect primary rat retinal glial cells and induce gene expression of inflammatory cytokines. *Curr. Eye Res.*, 16, 782–791 (1997).

37) Daenke, S., McCracken, S. A. and Booth, S. Human T-cell leukaemia/lymphoma virus type 1 syncytium formation is regulated in a cell-specific manner by ICAM-1, ICAM-3 and VCAM-1 and can be inhibited by antibodies to integrin β2 or β7. *J. Gen. Virol.*, 80, 1429–1436 (1999).

38) Sommerfelt, M. A. and Weiss, R. A. Receptor interference groups of 20 retroviruses plating on human cells. *Virology*, 176, 58–69 (1990).

39) Li, Q. X., Camerini, D., Xie, Y., Greenwald, M., Kuritzkes, D. R. and Chen, I. S. Syncytium formation by recombinant HTLV-II envelope glycoprotein. *Virology*, 218, 279–284 (1996).

40) Browning, J., Horner, J. W., Pettoello-Mantovani, M., Raker, C., Yurasov, S., DePinho, R. A. and Goldstein, H. Mice transgenic for human CD4 and CCR5 are susceptible to HIV infection. *Proc. Natl. Acad. Sci. USA*, 94, 14637–14641 (1997).

41) Wei, P., Garber, M. E., Fang, S. M., Fischer, W. H. and Jones, K. A. A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA. *Cell*, 92, 451–462 (1998).